

Dear colleagues,

We are greatly impressed by the feedback we have received from the first newsletter and by the increasing number of new affiliates.

In line with the aim of our project, we would like to share with you our recent insight in the hot and controversial topic of drug eluting stent thrombosis. The data are collected from three thousand patients treated with drug eluting stent in four European centers and followed throughout a period of 18 months. The study analyses the incidence and the predictors stent thrombosis and investigate the role of thienopyridine therapy.

As in the previous newsletter we propose a brief questionnaire in order to have a feed-back from your personal experience.

- 1) For how long do you prescribe dual antiplatelet therapy to patients who received drug eluting stent?
 - a) 6 months
 - b) 12 months
 - c) life long

- 2) Have you ever recorded very late (beyond 12 months) drug eluting stent thrombosis in patients with or without dual antiplatelet therapy?
 - a) yes, also in patients with dual antiplatelets
 - b) yes, only in patients without dual antiplatelets
 - c) no

- 3) Which is the rate of subacute (30days) stent thrombosis in your experience
 - a) <0.5%
 - b) 0.5-1%
 - c) 1-2%
 - d) 2-3%
 - d) 3-5%
 - e) >5%

4) Which is the rate of late (30days-one year) stent thrombosis in your experience

- a) <0.5%
- b) 0.5-1%
- c) 1-2%
- d) 2-3%
- d) 3-5%
- e) >5%

5) Which is the rate of very late (>one year) stent thrombosis in your experience

- a) <0.5%
- b) 0.5-1%
- c) 1-2%
- d) 2-3%
- d) 3-5%
- e) >5%

Sincerely,

Antonio Colombo, MD
Director Cardiac Catheterization Laboratory
Columbus Hospital, Milan

Flavio Airoldi, MD